[go: up one dir, main page]

CL2016000397A1 - Tratamiento contra el cáncer - Google Patents

Tratamiento contra el cáncer

Info

Publication number
CL2016000397A1
CL2016000397A1 CL2016000397A CL2016000397A CL2016000397A1 CL 2016000397 A1 CL2016000397 A1 CL 2016000397A1 CL 2016000397 A CL2016000397 A CL 2016000397A CL 2016000397 A CL2016000397 A CL 2016000397A CL 2016000397 A1 CL2016000397 A1 CL 2016000397A1
Authority
CL
Chile
Prior art keywords
cancer treatment
tsa
tricotastin
tricostatin
aurka
Prior art date
Application number
CL2016000397A
Other languages
English (en)
Inventor
Polymeropoulos Mihael
William Licamele Louis
Lavedan Christian
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2016000397A1 publication Critical patent/CL2016000397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento contra el cancer que comprende la administración de TRICOTASTINA A TSA. El uso de tricostatina A TSA que es útil para preparar una composición farmacéutica que sirve para disminuir el nivel de expresión de la aurora quinasa A AURKA en un individuo.
CL2016000397A 2013-08-22 2016-02-22 Tratamiento contra el cáncer CL2016000397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22

Publications (1)

Publication Number Publication Date
CL2016000397A1 true CL2016000397A1 (es) 2017-03-17

Family

ID=51794948

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000397A CL2016000397A1 (es) 2013-08-22 2016-02-22 Tratamiento contra el cáncer

Country Status (12)

Country Link
US (5) US20160199323A1 (es)
EP (2) EP3616754A1 (es)
JP (4) JP2016528297A (es)
KR (5) KR20230047203A (es)
CN (2) CN105579101A (es)
AU (4) AU2014308700A1 (es)
CA (1) CA2921036A1 (es)
CL (1) CL2016000397A1 (es)
EA (1) EA037667B1 (es)
ES (1) ES2755983T3 (es)
MX (1) MX381429B (es)
WO (1) WO2015027121A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230047203A (ko) * 2013-08-22 2023-04-06 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
CN113244205A (zh) * 2013-08-22 2021-08-13 万达制药公司 多发性骨髓瘤的治疗
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
US20250161242A1 (en) * 2022-03-01 2025-05-22 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
CA3002661C (en) 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
JP2009538318A (ja) 2006-05-26 2009-11-05 セルジーン・コーポレーション 併用療法において免疫調節化合物を用いる方法及び組成物
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9670549B2 (en) * 2011-11-10 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signatures of neoplasm responsiveness to therapy
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
CN113244205A (zh) 2013-08-22 2021-08-13 万达制药公司 多发性骨髓瘤的治疗
KR20230047203A (ko) * 2013-08-22 2023-04-06 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료

Also Published As

Publication number Publication date
KR20170126018A (ko) 2017-11-15
KR20160033779A (ko) 2016-03-28
JP2021105005A (ja) 2021-07-26
EA037667B1 (ru) 2021-04-28
MX2016002307A (es) 2016-06-15
AU2014308700A1 (en) 2016-02-25
CA2921036A1 (en) 2015-02-26
EP3036007A2 (en) 2016-06-29
KR102315528B1 (ko) 2021-10-21
AU2022202183B2 (en) 2023-09-28
AU2022202183A1 (en) 2022-04-21
EP3616754A1 (en) 2020-03-04
MX381429B (es) 2025-03-12
US20190211107A1 (en) 2019-07-11
NZ716668A (en) 2021-02-26
US11667718B2 (en) 2023-06-06
KR20230047203A (ko) 2023-04-06
US20160199323A1 (en) 2016-07-14
WO2015027121A3 (en) 2015-05-14
KR20210013343A (ko) 2021-02-03
EP3036007B1 (en) 2019-10-09
US20210324093A1 (en) 2021-10-21
KR20210127821A (ko) 2021-10-22
JP2019167351A (ja) 2019-10-03
ES2755983T3 (es) 2020-04-24
US20180256522A1 (en) 2018-09-13
US11078289B2 (en) 2021-08-03
EA201690445A1 (ru) 2016-06-30
JP2023088996A (ja) 2023-06-27
CN110585184A (zh) 2019-12-20
CN105579101A (zh) 2016-05-11
JP2016528297A (ja) 2016-09-15
AU2021261882B2 (en) 2022-04-14
AU2019261718A1 (en) 2019-11-28
WO2015027121A2 (en) 2015-02-26
AU2021261882A1 (en) 2021-12-02
US20230257471A1 (en) 2023-08-17
US10265282B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
CL2016000397A1 (es) Tratamiento contra el cáncer
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica